The FDA approved TMS NeuroStar device to treat Obsessive-Compulsion Disorder in May 2022.
How do we get higher remission rates with rTMS?
TMS researchers such as Jonathan Downar are making progress in identifying subtypes of depression based on functional connectivity of networks associated with symptom domains that occur across the spectrum of diagnoses in the DSM. If we can identify the pathological networks, and target their nodes on the surface of the cortex, we can make neuroanatomical-clinical formulations of our patients and more effectively treat patients with TMS.
But how do we know where to treat each patient?
In order to individualize treatment of patients, we must identify the subtype of depression that each patient has, according to which netowork is not funcitoning properly, and then stimulate the pathological network, rather than our current method of stimulating everybody over the DLPFC.
How does TMS work, on the network level?
The brain is complicated, and processing the signals of circuits is what the brain does to carry out its functions. Typically, in rTMS, we stimulate the DLPFC, which is connected to the striatum & basal ganglia, which is connected to the thalamus, which projects back up to the DLPFC, a loop.
Read the full story here: https://www.clinicaltmssociety.org/newsletter/article/its-all-about-remission-jonathan-downar-md-lecture-recap-2017-annual-meeting
You Might Also Enjoy...
The FDA approved TMS NeuroStar device to treat Obsessive-Compulsion Disorder in May 2022.
Read about how we use magnetic resonance therapy (MeRT) as a customized use of Transcranial Magnetic Stimulation (TMS).
While TMS is an FDA approved treatment to relieve symptoms of treatment resistant depression, it can be used for many off-label purposes as well.
Historic events have unfolded in the past few year and studies have shown that there is a link between the current state of the news and individual's mental health.
The World Health Organization (WHO) released a scientific brief that stated that there was a dramatic 25% increase in the global prevalence of depression and anxiety during the first year of the COVID-19 pandemic.
Happy Brain Awareness Week! Read more about the effect of different brain chemical messengers and their effect on mental health and every day functioning.